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Prostate Specific Membrane Antigen mRNA in Blood as a Potential 
Predictor of Biochemical Recurrence after Radical Prostatectomy
We investigated whether the detection of prostate specific membrane antigen (PSMA) in 
blood preoperatively has predictive value for biochemical recurrence (BCR) after radical 
prostatectomy in patients with prostate cancer. All 134 patients scheduled to receive radical 
prostatectomy for prostate cancer were prospectively enrolled. The authors used nested 
reverse transcriptase-polymerase chain reaction (RT-PCR) assay to detect PSMA mRNA-
bearing cells in peripheral blood, and analyzed the ability of PSMA mRNA positivity to 
predict BCR after surgery. PSMA-mRNA was detected in 24 (17.9%) patients by RT-PCR. 
Over a median follow-up of 20 months (range, 3 to 46 months), BCR developed in 15 
patients (11.2%) and median time to BCR was 7 months (range, 3 to 25 months). Kaplan-
Meier analysis revealed a significant difference between those positive or negative for 
PSMA in terms of recurrence-free actuarial probability (log rank P=0.0039). Multivariate 
analysis showed that positivity for PSMA mRNA (HR: 3.697, 95% CI 1.285-10.634, P=0.015) 
and a biopsy Gleason score of ≥7 (HR: 4.500, 95% CI 1.419-14.274, P=0.011) were 
independent preoperative predictors of BCR. The presence of PSMA mRNA in peripheral 
blood can be used to predict BCR after radical prostatectomy.
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INTRODUCTION
Radical prostatectomy is considered a standard treatment for 
patients with localized prostate cancer. However, some patients 
experience recurrence after surgery, and this is known to be as-
sociated with prostate-specific antigen (PSA), Gleason score 
(GS), and disease stage. Furthermore, recurrence is believed to 
be caused by clinically undetectable amounts of micrometastat-
ic prostate cancer (1). To predict recurrence after treatment ac-
curately, an improved method for detecting micrometastatic 
prostate cancer is required. Several means of detecting prostate 
cancer cells in blood have been used during investigations on 
the molecular staging of prostate cancer, and one of these tech-
niques, namely, reverse transcriptase-polymerase chain reac-
tion (RT-PCR), has been used on several occasions to detect cir-
culating prostate cells (2, 3). 
  Prostate specific membrane antigen (PSMA) is a 750-amino-
acid, type 2 transmembrane glycoprotein expressed on prostate 
epithelial cells, and has been shown to be highly prostate spe-
cific and to be expressed in a disease progression dependent 
manner (4-8). Many studies have been performed to determine 
the predictive value of PSMA as a predictor for accurate patho-
logic stage, but their results are still inconclusive (9-11). Further-
more, studies on the prognosis of prostate cancer following sur-
gery according to PSMA detection are limited (8, 12).
  In the present study, we investigated whether the presence of 
PSMA mRNA in blood has predictive value for biochemical re-
currence (BCR) after radical prostatectomy. 
MATERIALS AND METHODS
Patient selection
One hundred and thirty four patients scheduled to receive radi-
cal prostatectomy for prostate cancer at our institution from 
March 2005 to October 2008 were prospectively enrolled. Eligi-
ble patients were required to have histologically proven adeno-
carcinoma of the prostate; patients that previously undergone 
hormonal or radiation therapy were excluded. The Institutional 
Review Board of the Korean National Cancer Center approved 
the study protocol (NCCNCS 05-049) and informed consent 
was obtained from all patients for the collection of clinical data, 
and for serum and tissue samples. Patients underwent radical 
prostatectomy and standard pelvic lymph node dissection. Post-
operatively, no adjuvant hormonal or radiotherapy was per-
formed until BCR had developed.
Blood samples, RNA extraction, and reverse transcription 
Peripheral blood samples were obtained preoperatively. Nucle-Joung JY, et al.  •  PSMA mRNA Detection in Prostate Cancer
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ated cell fractions were isolated from 5 mL whole blood samples 
(anti-coagulated with EDTA [ethylenediaminetetracetic acid]) 
by Percoll gradient centrifugation (Amersham Biosciences, Up-
psala, Sweden). RNA extraction and reverse transcription were 
performed as described in a previous report (13).
Polymerase chain reaction and nested PCR 
All primers used in this study were custom designed by Bioneer 
(Daejeon, Korea). The intron spanning primer pairs specific for 
human PSMA were:- sense, 5´-CAG ATA TGT CAT TCT GGG AG 
GTC-3´; antisense, 5´-AAC ACC ATC CCT CCT CGA ACC-3´. For 
nested PCR, the sense and antisense primers were replaced by 
5´-CCT AAC AAA AGA GCT GAA AAG CCC-3´ and 5´-ACT GTG 
ATA CAG TGG ATA GCC GCT-3´ respectively. The housekeep-
ing gene β-actin was used as an internal control. PCR reactions 
were performed in a total volume of 20 μL containing 1 μL of RT 
product, 1 μM of sense and 1 μM of antisense primer, 10 mM 
Tris-HCl (pH 9.0), 30 mM KCl, 1.5 mM MgCl2, 0.25 mM of each 
dNTP, and 1 U Taq-DNA polymerase (Bioneer, Daejeon, Korea). 
Amplification of cDNA (0.5 μg) was performed using a tube-con-
trolled thermal cycler (MJ Research, Waltham, MN, USA). For 
nested PCR, 2 μL of PCR products were amplified for an addi-
tional 40 cycles using the same reagents, but original primers 
were replaced with nested primers.
RT-PCR assay sensitivity 
RT-PCR assay sensitivity was determined by assaying dilutions 
of LNCaP human prostate cancer cells in peripheral blood mono-
nuclear cell (PBMC) suspensions prepared from normal donors. 
In our previous study, it was found that the mRNAs of 10 LNCaP 
cells diluted in 10
7 PBMCs from healthy donors could be detect-
ed by nested RT-PCR for PSMA. In the present study, all sam-
ples subjected to qualitative RT-PCR for PSMA mRNA were as-
sayed several times to confirm test reproducibility, and results 
for individual samples were only subjected to further analysis 
after initial test results (positive or negative) had been confirmed 
by retesting.
Analysis of PCR products 
PCR products (10 μL) premixed with loading dye in the PCR kit 
(Bioneer) and loaded into 2% agarose gel in TBE buffer (0.1 M 
Tris [pH 8.4], 90 mM boric acid, 1 mM EDTA), and subjected to 
electrophoresis for 60 min. Gels were stained with ethidium bro-
mide and amplicons were visualized using a UV-transillumina-
tor. To ensure internal consistency, all RT-PCR assay results were 
scored by two investigators unaware of clinical or pathologic data.
Pathological analysis
Complete transverse sections were taken from the apex to base 
of excised prostrates at 4 mm intervals. All excised prostates were 
examined by a single pathologist and staged according to the 
TNM system of the International Union Against Cancer. Glea-
son scores, the presence of extracapsular extension, and evidence 
of seminal vesicle invasion were documented. 
Follow up
All 134 patients were scheduled for a digital rectal examination 
and a serum PSA evaluation every 3 months for the first two 
postoperative years, biennially during the third to the fifth years, 
and annually thereafter. BCR was defined as a sustained PSA 
elevation of >0.4 ng/mL on two or more occasions. Clinical out-
come analysis was performed using the NCC prostate cancer 
database of clinical and pathologic data.
Statistical analysis
Initially, Fisher’s exact test was used to determine whether PSMA 
positivity was related to clinical factors. BCR-free survival curves 
were generated separately using the Kaplan-Meier method for 
patients with positive and negative RT-PCR results, and differ-
ences between the two curves were evaluated using the log-rank 
test. To identify factors capable of predicting BCR, univariate 
and multivariate recurrence analyses were performed using the 
Cox proportional hazards regression model. Statistical signifi-
cance was accepted for P values of <0.05. All analyses were per-
formed using the SPSS software package (version 12.0 for Win-
dows 2000
®, SPSS, Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
Mean patient age of the 134 patients was 60.3 years (range 49 to 
70). Preoperatively, initial preoperative serum PSA levels ranged 
from 1.9 to 40.0 ng/mL (mean: 10.4 ng/mL, median: 7.8 ng/mL). 
In terms of biopsy Gleason scores, 86 patients (64.2%) had low 
grade (GS ≤6) disease and 48 (35.8%) high grade (GS ≥7) disease. 
128 patients (94%) showed clinically prostate-confined disease 
(≤cT2) and the other 8 (6%) extraprostatic disease (≥cT3). With 
regard to pathologic stage, prostate-confined disease (≤pT2) 
was encountered in 98 (73.9%) patients and pT3 disease in 35 
(26.1%) patients. No patients were found to have lymph node 
or distant metastasis. Clinical and pathological data before and 
after surgery are listed in Table 1.
PSMA detection by RT-PCR in peripheral blood 
PSMA-mRNA was detected in 24 (17.9%) patients by RT-PCR, 
i.e., in 14 of 97 patients (14.4%) with pT2 disease and in 9 of 35 
patients (25.7%) with pT3 disease. Patients with extraprostatic 
extension (pT3) tended to have a PSMA mRNA positive status, 
but this was not statistically significant (P=0.192). With regard 
to the relationship between PSMA positivity and other clinical 
parameters, the presence of PSMA was not found to be related 
to serum PSA, Gleason score, or lymphovascular (LV) emboli Joung JY, et al.  •  PSMA mRNA Detection in Prostate Cancer
http://jkms.org   1293 DOI: 10.3346/jkms.2010.25.9.1291
(Table 1).
Biochemical recurrence following radical prostatectomy
Follow-up data were available for all 134 patients with a median 
follow-up of 20 months (range, 3 to 46 months). BCR developed 
in 15 patients (11.2%) and median time to BCR was 7 months 
(range: 3-25 months). Of the 15 patients that developed BCR, 13 
underwent hormone therapy, 1 patient is being observed using 
PSA check-ups, and the other 1 underwent salvage external beam 
radiation therapy. No deaths occurred during the study period. 
Kaplan-Meier analysis revealed a significant difference between 
those positive or negative for PSMA in terms of recurrence-free 
actuarial probability (log rank P=0.004, Fig. 1). Cox regression 
hazard analysis showed that positivity for PSMA mRNA (HR: 
3.697, 95%CI 1.285-10.634, P=0.015) and a biopsy GS of ≥7 (HR: 
4.500, 95%CI 1.419-14.274, P=0.011) independently predicted 
BCR. On the other hand, in terms of postoperative predictors of 
BCR, only pathologic T3 stage (HR: 4.016, 95%CI 1.194-13.511, 
P=0.025) was found to be significant (Table 2). 
DISCUSSION
The success of radical prostatectomy is dependent on the con-
finement of the cancer to the prostrate. Pretreatment PSA level, 
biopsy GS, and clinical stage have been considered to be pre-
operative predictors of organ confinement. However, clinical 
stage based on digital rectal and radiologic examinations, is in-
adequate for predicting the presence of extraprostatic extension 
Table 1. Patient characteristics and PSMA detection by RT-PCR
Classification
No. of patients (%)
P value Total  
n=134
RT-PCRPSMA (+)  
n=24 (17.9%)
RT-PCR PSMA (-)  
n=110 (82.1%)
PSA (ng/mL)
   <4.1
   4.1-10.0
   10.1-20.0
   >20.1
11 (8.2)
  79 (59.0)
  32 (23.9)
12 (9.0)
  2 (18.2)
16 (20.3)
3 (9.4)
  3 (25.0)
    9 (81.8)
  63 (79.7)
  29 (90.6)
    9 (75.0)
0.514
GS (biopsy)
   2-6
   7
   8-10
  86 (64.2)
  36 (26.8)
12 (9.0)
12 (14.0)
11 (30.6)
1 (8.3)
  
74 (86.0)
  25 (69.4)
  11 (91.7)
0.061
Clinical stage
   cT1c
   cT2a-cT2b
   cT2c
   ≥cT3
  69 (51.5)
  35 (26.1)
  22 (16.4)
  8 (6.0)
11 (15.9)
  8 (22.9)
  4 (18.2)
  1 (12.5)
 
 58 (84.1)
  27 (77.1)
  18 (81.8)
    7 (87.5)
0.819
Pathologic stage
   pT0N0M0
   pT2N0M0
   pT3N0M0
 
 2 (1.5)
  97 (72.4)
  35 (26.1)
  1 (50.0)
14 (14.4)
  9 (25.7)
 
   1 (50.0)
  83 (85.6)
  26 (74.3)
0.192
GS (surgical)
   Non-available
   2-6
   7
   8-10
  2 (1.5)
  59 (44.0)
  61 (45.5)
12 (9.0)
  1 (50.0)
  9 (15.3)
11 (18.0)
  3 (25.0)
    1 (50.0)
  50 (84.7)
  50 (82.0)
    9 (75.0)
0.553
LV emboli
   Positive
   Negative
12 (9.0)
122 (91.0)
  
2 (16.7)
22 (18.0)
  10 (83.3)
100 (82.0)
0.906
SV invasion
   Positive
   Negative
10 (7.5)
124 (92.5)
  3 (30.0)
21 (16.9)
    
7 (70.0)
103 (83.1)
0.300
Surgical margin
   Positive
   Negative
  47 (35.1)
  87 (64.9)
  7 (14.9)
17 (19.5)
  40 (85.1)
  70 (80.5)
0.503
PSA, prostate-specific antigen; RT-PCR, reverse transcriptase-polymerase chain 
reaction; PSMA, prostate specific membrane antigen; GS, Gleason score; NHT, 
neoadjuvant hormonal therapy; LV, lymphovascular; SV, seminal vesicle.
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Fig. 1. Kaplan-Meier plot of the likelihood of RT-PCR PSMA positive cases remaining 
free of biochemical recurrence after radical prostatectomy (log rank P=0.0039).
PSMA, prostate specific membrane antigen; BCR, biochemical recurrence.
Table 2. Univariate and multivariate analysis of prognostic factors of biochemical 
recurrence
Variables HR 95% CI P value
Univariate
   Preoperative variables
      PSA ≥10
      Biopsy GS 7 or greater
      Clinical stage ≥ T3
      RT-PCR PSMA positivity
2.433
5.607
1.989
4.075
0.865-6.845
1.782-17.639
0.446-8.868
1.440-11.531
0.092
0.003
0.367
0.008
   Postsurgical variables
      Pathologic stage ≥ T3
      GS 7 or greater
      LV tumor emboli
      Positive surgical margin
6.439
3.437
5.486
1.932
2.198-18.859
0.969-12.189
1.873-16.068
0.694-5.384
0.001
0.056
0.002
0.208
Multivariate
   Preoperative variables
      PSA ≥10
      Biopsy GS 7 or greater
      Clinical stage ≥T3
      RT-PCR PSMA positivity
2.254
4.500
2.605
3.697
0.759-6.692
1.419-14.274
0.550-12.332
1.285-10.634
0.143
0.011
0.227
0.015
   Postsurgical variables
      Pathologic stage ≥T3
      GS 7 or greater
      LV tumor emboli
      Positive surgical margin
4.016
1.830
2.278
1.489
 1.194-13.511
0.475-7.046
0.697-7.449
0.528-4.200
0.025
0.380
0.173
0.451
PSA, prostate-specific antigen; GS, Gleason score; SV, seminal vesicle; LV, lympho-
vascular; RT-PCR, reverse transcriptase-polymerase chain reaction; HR, hazard ratio; 
CI, confidence interval; PSMA, prostate specific manbrane antigen; LV, lymphovascular.Joung JY, et al.  •  PSMA mRNA Detection in Prostate Cancer
1294   http://jkms.org DOI: 10.3346/jkms.2010.25.9.1291
(14). Furthermore, biopsy-based Gleason scores are unsuitable 
predictors, because cancers graded by biopsy often differ from 
final surgical specimen findings (15). Moreover, pretreatment 
PSA levels may be dependent on benign conditions, such as, 
benign prostatic hyperplasia and inflammation in addition to 
tumor burden (16). Therefore, new strategies that can improve 
the accuracy of tumor staging are urgently required to identify 
appropriate candidates for radical prostatectomy.
  Regarding studies on the molecular staging of prostate can-
cer, many researchers have attempted to detect circulating can-
cer cells in peripheral blood or bone marrow using molecular 
techniques (2, 3). In particular, RT-PCR is a potentially powerful 
molecular tool for detecting small numbers of cancer cells, and 
can detect tumor specific marker-expressing cells that are oth-
erwise undetectable. In terms of molecular markers specific for 
prostate cancer, PSA, prostate stem cell antigen (PSCA), PSMA, 
and human kallikrein-2 (hK2) have been investigated (17-19).
  PSMA is a typical cell-surface marker of prostate cancer, and 
is an integral type 2 membrane protein that is abundantly and 
almost universally expressed in prostate carcinoma (4-6). Based 
on studies, which included patients with metastases, the rate of 
PSMA detection in blood by RT-PCR ranges from 39 to 91%, and 
in patients with localized prostate cancer, PSMA positivity ranges 
from 10 to 72% (10, 20-22). In the present study, PSMA-mRNA 
was detected in 14.4% with pT2 disease and in 25.7% with pT3 
disease. The wide range of reported positivities is probably due 
to different patient characteristics and RT-PCR assay sensitivi-
ties. With regard to relationship between RT-PCR findings and 
clinical parameters, several studies have failed to reveal a corre-
lation between PSMA positivity and pathologic stage, GS, or se-
rum PSA level, which concurs with our observations (10, 20-22).
  Theoretically, PSMA detection by RT-PCR in patients with lo-
calized prostate cancer suggests the dissemination of potential 
micrometastatic disease, which cannot be detected by even post-
operative pathologic analysis. However, previous studies have 
focused on determining the accuracies of RT-PCR results in terms 
of predicting pathologic stage in patients with prostate cancer 
(9-11), and to our knowledge, studies conducted over the past 
10 yr on the use of molecular tools, such as, RT-PCR, for accurate 
pathologic staging have, as yet, failed to yield consistent results. 
However, given that pathologic stage and GS in surgical speci-
mens are well-established prognostic factors of recurrence after 
surgery, we undertook to evaluate the predictive value of circu-
lating tumor cells preoperatively in patients scheduled to un-
dergo definitive treatment, such as surgery or radiation therapy. 
Few reports have presented relations between RT-PCR and prog-
nostic value, such as, recurrence-free survival, and the role of 
RT-PCR in this context has not been determined (8, 12). Our find-
ing that the presence of PSMA mRNA in peripheral blood can 
predict BCR after radical prostatectomy in patients with pros-
tate cancer has substantial practical implications. Moreover, our 
results strongly indicate that PSMA detection in peripheral blood 
can predict disease recurrence after surgery, and show that nest-
ed RT-PCR for PSMA is a more potent predictive parameter than 
clinical parameters, such as, preoperative PSA level, biopsy GS, 
and clinical stage. Accordingly, our findings suggest that RT-PCR 
assays for PSMA could help identify appropriate patients for rad-
ical prostatectomy. Furthermore, a positive RT-PCR PSMA sta-
tus was found to be a potent independent postsurgical predic-
tor of recurrence by multivariate analysis incorporating postsur-
gical parameters, such as, pathological stage, GS, LV tumor em-
boli, and a positive surgical margin (RT-PCR PSMA [HR: 3.887, 
95%CI 1.284-11.771, P=0.016] stage ≥pT3 [HR: 2.254, 95%CI 
0.915-11.052, P=0.069]). Finally, our findings also suggest that 
PSMA status should be closely followed to detect localized dis-
ease recurrence.
  The present study has several limitations that require consid-
eration. First, it is controversial as to whether circulating tumor 
cells always cause recurrence. Therefore, additional follow-up is 
required to assess the significance of circulating prostate cancer 
cells in peripheral blood. Second, over a median follow-up of 20 
months (range, 3 to 46 months), BCR developed in our cohort 
in less than 25 months (median 7 months, range 3 to 25), which 
is too short a follow-up to enable us to comment on long-term 
results or on delayed BCR development.
  In conclusion, PSMA mRNA detection by RT-PCR in periph-
eral blood can be a potent preoperative predictor of BCR after 
radical prostatectomy.
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